What question did this study set out to answer?

The research aims to identify optimal conditions for rechallenging immune-checkpoint inhibitors in metastatic clear-cell renal cell carcinoma.

April 25, 2026Open Access

Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study

Key Points

The research aims to identify optimal conditions for rechallenging immune-checkpoint inhibitors in metastatic clear-cell renal cell carcinoma.
Analyzed global real-world data on immune-checkpoint inhibitor rechallenge outcomes.
Evaluated treatment intervals and their impact on response rates.
Recommended prospective trials to explore timing as a surrogate marker.
Patients with longer intervals (≥6 months) between immune-checkpoint inhibitor treatments showed improved outcomes.
Timing of treatment rechallenge appears to be a significant factor in efficacy.

Abstract

Our results outline opportunities for optimal ICI rechallenge, regardless of the prior immunotherapy administered. Improved outcomes with longer intervals (≥6 months) between treatments suggest timing is a key driver of efficacy and should be investigated in prospective trials as a surrogate marker of likely treatment response.

Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study

Key Points

Abstract

Cite This Study